Contents,Journal of the American College of Cardiology

当前位置： X-MOL 学术 › J. Am. Coll. Cardiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Contents
Journal of the American College of Cardiology ( IF 21.7 ) Pub Date : 2024-11-04 , DOI: 10.1016/s0735-1097(24)10051-4

Section snippets

Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program

1979Milton Packer, João Pedro Ferreira, Javed Butler, Gerasimos Filippatos, James L. Januzzi, Jr, Sandra González Maldonado, Marina Panova-Noeva, Stuart J. Pocock, Jürgen H. Prochaska, Maral Saadati, Naveed Sattar, Mikhail Sumin, Stefan D. Anker, Faiez ZannadThe authors performed the first mechanistic validation study of large-scale proteomics in a double-blind randomized trial of any treatment in heart failure. Among 2,155 proteins assessed in 1,120 EMPEROR participants, 25 were most

Artificial Intelligence in Cardiovascular Clinical Trials

2051Jonathan W. Cunningham, William T. Abraham, Ankeet S. Bhatt, Jessilyn Dunn, G. Michael Felker, Sneha S. Jain, Christopher J. Lindsell, Matthew Mace, Trejeeve Martyn, Rashmee U. Shah, Geoffrey H. Tison, Tala Fakhouri, Mitchell A. Psotka, Harlan Krumholz, Mona Fiuzat, Christopher M. O’Connor, Scott D. Solomon, the Heart Failure CollaboratoryRandomized clinical trials are the gold standard for evaluating cardiovascular therapies but are expensive, lengthy, and insufficiently diverse.

A Guide to Implementation Science for Phase 3 Clinical Trialists: Designing Trials for Evidence Uptake

2063Harriette G.C. Van Spall, Laura Desveaux, Tracy Finch, Cara C. Lewis, George A. Mensah, Yves Rosenberg, Kavita Singh, Francois Venter, Bryan J. Weiner, Faiez ZannadThe delayed uptake of evidence-based cardiovascular treatments highlights the need for attention to implementation science. This review describes the goals, frameworks, and strategies used in implementation science. Some approaches used for implementation well after a trial has ended can be incorporated into the design of phase 3

ONLINE LETTER TO THE EDITOR Let Us Focus on Angina Mechanisms in Many, Not Just Typical Symptoms in a Few

e275Christiaan J.M. Vrints

ONLINE LETTER TO THE EDITOR Reply

Christopher A. Rajkumar, Rasha K. Al-Lamee

ONLINE LETTER TO THE EDITOR Gender Disparities in Cardiovascular Literature: Expanding the Scope and Solutions

e279Ruirui Hou, Jian Ren

ONLINE LETTER TO THE EDITOR Gender Diversity: Will Mandates Be the Best Way to Go?

e281Merle Myerson

ONLINE LETTER TO THE EDITOR Reply

Ridhima Goel, Birgit Vogel, Roxana Mehran

ONLINE LETTER TO THE EDITOR To Pretreat or Not to Pretreat: That Is the Question

e285Ali Dahhan, Mohammad Bilal Memon, Zachariah Zaaza, Ian Jennings, Hanan Gruhonjic

ONLINE LETTER TO THE EDITOR Reply

Manuel Almendro-Delia

ONLINE LETTER TO THE EDITOR The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy

e289Kuan-Yu Chi, Cesia Gallegos-Kattán, Nikhil V. Sikand, Marc D. Samsky, Michael G. Nanna

ONLINE LETTER TO THE EDITOR Reply

Aldostefano Porcari, Julian Gillmore, Adam Ioannou, Scott Solomon, Marianna Fontana

ONLINE LETTER TO THE EDITOR Vive la Différence: Addressing Graft Failure in Women

e293Xuan Jiang, Tianxiang Gu

ONLINE LETTER TO THE EDITOR Advancing Women's CABG Outcomes: Broader Research and Community Needs

e295Yuli Guo, Ruirui Hou

ONLINE LETTER TO THE EDITOR Reply

Sigrid Sandner,

中文翻译：

内容

部分片段

重申心力衰竭患者伴随 SGLT2 抑制的机制蛋白质组学特征：EMPEROR 计划的验证队列

1979 年Milton Packer、João Pedro Ferreira、Javed Butler、Gerasimos Filippatos、James L. Januzzi， Jr、Sandra González Maldonado、Marina Panova-Noeva、Stuart J. Pocock、Jürgen H. Prochaska、Maral Saadati、Naveed Sattar、Mikhail Sumin、Stefan D. Anker、Faiez Zannad作者在一项针对心力衰竭任何治疗的双盲随机试验中进行了大规模蛋白质组学的首次机制验证研究。在 1,155 名 EMPEROR 参与者评估的 1,120 种蛋白质中，有 25 种是

人工智能在心血管临床试验中的应用

2051 年Jonathan W. Cunningham， William T. Abraham， Ankeet S. Bhatt， Jessilyn Dunn， G. Michael Felker， Sneha S. Jain， Christopher J. Lindsell， Matthew Mace， Trejeeve Martyn， Rashmee U. Shah， Geoffrey H. Tison， Tala Fakhouri， Mitchell A. Psotka， Harlan Krumholz， Mona Fiuzat， Christopher M. O'Connor， Scott D. Solomon，心力衰竭合作实验室随机临床试验是评估心血管治疗的金标准，但价格昂贵，冗长且不够多样化。

3 期临床试验员实施科学指南：设计证据吸收试验

2063 年Harriette GC Van Spall、Laura Desveaux、Tracy Finch、Cara C. Lewis、George A. Mensah、Yves Rosenberg、Kavita Singh、Francois Venter、Bryan J. Weiner、Faiez Zannad循证心血管治疗的延迟采用凸显了关注实施科学的必要性。本综述描述了实施科学中使用的目标、框架和策略。一些用于在试验结束后实施的方法可以纳入第 3 阶段的设计中